CTOs on the Move

Genmab

www.genmab.com

 
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.genmab.com
  • 902 Carnegie Center Suite 301
    Princeton, NJ USA 08540
  • Phone: 609.430.2481

Executives

Name Title Contact Details
Anthony Mancini
 Executive Vice President and Chief Operating Officer Profile

Similar Companies

Batu Biologics

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.

Protea Biosciences

Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Immunotec

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary   T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.   The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection, or LTBI. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval (PMA) from the Food and Drug Administration (FDA), in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan.   We are a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).

PathAI

PathAI is the world`s leading PathAI`s mission is to advance medicine with intelligent pathology. PathAI`s platform provides end-to-end data-driven pathology analysis, resulting in fast, accurate and standardized pathologic diagnoses.

Enthrive

Enthrive is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.